JP2015504902A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015504902A5 JP2015504902A5 JP2014553589A JP2014553589A JP2015504902A5 JP 2015504902 A5 JP2015504902 A5 JP 2015504902A5 JP 2014553589 A JP2014553589 A JP 2014553589A JP 2014553589 A JP2014553589 A JP 2014553589A JP 2015504902 A5 JP2015504902 A5 JP 2015504902A5
- Authority
- JP
- Japan
- Prior art keywords
- substituents
- optionally substituted
- substituted
- heteroaryl
- aryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000001424 substituent group Chemical group 0.000 claims description 72
- 125000000217 alkyl group Chemical group 0.000 claims description 15
- 125000001072 heteroaryl group Chemical group 0.000 claims description 13
- 125000000623 heterocyclic group Chemical group 0.000 claims description 12
- 125000003118 aryl group Chemical group 0.000 claims description 11
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 9
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 9
- 229910052757 nitrogen Inorganic materials 0.000 claims description 8
- 229910052760 oxygen Inorganic materials 0.000 claims description 8
- 229910052717 sulfur Inorganic materials 0.000 claims description 8
- 125000005842 heteroatom Chemical group 0.000 claims description 7
- -1 5-[(3aS, 4S, 6aR) -2-oxohexahydro-1H-thieno [3,4-d] imidazol-4-yl] pentanoyl Chemical group 0.000 claims description 5
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 5
- 125000003342 alkenyl group Chemical group 0.000 claims description 3
- 125000000304 alkynyl group Chemical group 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 claims 18
- 150000003839 salts Chemical class 0.000 claims 10
- 210000004027 cell Anatomy 0.000 claims 9
- 238000000034 method Methods 0.000 claims 9
- 239000000651 prodrug Substances 0.000 claims 9
- 229940002612 prodrug Drugs 0.000 claims 9
- 101150009274 nhr-1 gene Proteins 0.000 claims 7
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 210000001185 bone marrow Anatomy 0.000 claims 3
- 210000004700 fetal blood Anatomy 0.000 claims 3
- 150000003384 small molecules Chemical class 0.000 claims 3
- 210000000130 stem cell Anatomy 0.000 claims 3
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims 2
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims 2
- 102000000646 Interleukin-3 Human genes 0.000 claims 2
- 108010002386 Interleukin-3 Proteins 0.000 claims 2
- 102000004889 Interleukin-6 Human genes 0.000 claims 2
- 108090001005 Interleukin-6 Proteins 0.000 claims 2
- 102000036693 Thrombopoietin Human genes 0.000 claims 2
- 108010041111 Thrombopoietin Proteins 0.000 claims 2
- 230000010261 cell growth Effects 0.000 claims 2
- 108700014844 flt3 ligand Proteins 0.000 claims 2
- 239000003102 growth factor Substances 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 208000018706 hematopoietic system disease Diseases 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- 229940076264 interleukin-3 Drugs 0.000 claims 2
- 229940100601 interleukin-6 Drugs 0.000 claims 2
- 208000007056 sickle cell anemia Diseases 0.000 claims 2
- BGFHMYJZJZLMHW-UHFFFAOYSA-N 4-[2-[[2-(1-benzothiophen-3-yl)-9-propan-2-ylpurin-6-yl]amino]ethyl]phenol Chemical group N1=C(C=2C3=CC=CC=C3SC=2)N=C2N(C(C)C)C=NC2=C1NCCC1=CC=C(O)C=C1 BGFHMYJZJZLMHW-UHFFFAOYSA-N 0.000 claims 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 1
- 208000032467 Aplastic anaemia Diseases 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 208000018240 Bone Marrow Failure disease Diseases 0.000 claims 1
- 206010065553 Bone marrow failure Diseases 0.000 claims 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 1
- 206010053138 Congenital aplastic anaemia Diseases 0.000 claims 1
- 208000027205 Congenital disease Diseases 0.000 claims 1
- 201000004939 Fanconi anemia Diseases 0.000 claims 1
- 208000015872 Gaucher disease Diseases 0.000 claims 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 claims 1
- 208000029462 Immunodeficiency disease Diseases 0.000 claims 1
- 208000001019 Inborn Errors Metabolism Diseases 0.000 claims 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 claims 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 1
- 208000014767 Myeloproliferative disease Diseases 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
- 206010043395 Thalassaemia sickle cell Diseases 0.000 claims 1
- 208000002903 Thalassemia Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 210000003743 erythrocyte Anatomy 0.000 claims 1
- 210000003714 granulocyte Anatomy 0.000 claims 1
- 230000003394 haemopoietic effect Effects 0.000 claims 1
- 230000009033 hematopoietic malignancy Effects 0.000 claims 1
- 201000001505 hemoglobinuria Diseases 0.000 claims 1
- 210000005260 human cell Anatomy 0.000 claims 1
- 208000016245 inborn errors of metabolism Diseases 0.000 claims 1
- 208000015978 inherited metabolic disease Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 210000005259 peripheral blood Anatomy 0.000 claims 1
- 239000011886 peripheral blood Substances 0.000 claims 1
- 208000028529 primary immunodeficiency disease Diseases 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 0 CCCCc1c(c2ccc(*)cc2[n]2)c2nc(*)n1 Chemical compound CCCCc1c(c2ccc(*)cc2[n]2)c2nc(*)n1 0.000 description 1
- XQESRORWDXYILU-UHFFFAOYSA-N CNCCCN1CCCCC1 Chemical compound CNCCCN1CCCCC1 XQESRORWDXYILU-UHFFFAOYSA-N 0.000 description 1
- OBLKGLNRMMXCFW-LJGSYFOKSA-N CN[C@H](CC1)CC[C@@H]1N Chemical compound CN[C@H](CC1)CC[C@@H]1N OBLKGLNRMMXCFW-LJGSYFOKSA-N 0.000 description 1
- SIBCJMZHJZDUNK-UHFFFAOYSA-N COC(c1ccc2c3c(NCCCN4CCCCC4)ncnc3[nH]c2c1)=O Chemical compound COC(c1ccc2c3c(NCCCN4CCCCC4)ncnc3[nH]c2c1)=O SIBCJMZHJZDUNK-UHFFFAOYSA-N 0.000 description 1
- AZXXGVPWWKWGAE-UHFFFAOYSA-N C[n]1nnc(-c2ccc3c4c(NC(CC5)CCC5N)nc(Cc5ccccc5)nc4[nH]c3c2)n1 Chemical compound C[n]1nnc(-c2ccc3c4c(NC(CC5)CCC5N)nc(Cc5ccccc5)nc4[nH]c3c2)n1 AZXXGVPWWKWGAE-UHFFFAOYSA-N 0.000 description 1
- XCHLHUVAENNQGI-UHFFFAOYSA-N C[n]1nnc(-c2ccc3c4c(NCCCN5CCCCC5)ncnc4[nH]c3c2)n1 Chemical compound C[n]1nnc(-c2ccc3c4c(NCCCN5CCCCC5)ncnc4[nH]c3c2)n1 XCHLHUVAENNQGI-UHFFFAOYSA-N 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261591521P | 2012-01-27 | 2012-01-27 | |
| US61/591,521 | 2012-01-27 | ||
| PCT/CA2013/050052 WO2013110198A1 (en) | 2012-01-27 | 2013-01-25 | Pyrimido[4,5-b]indole derivatives and use thereof in the expansion of hematopoietic stem cells |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015504902A JP2015504902A (ja) | 2015-02-16 |
| JP2015504902A5 true JP2015504902A5 (enExample) | 2016-03-17 |
| JP6250556B2 JP6250556B2 (ja) | 2017-12-20 |
Family
ID=48872865
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014553589A Active JP6250556B2 (ja) | 2012-01-27 | 2013-01-25 | ピリミド［４，５−ｂ］インドール誘導体及び造血幹細胞の増殖におけるその使用 |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US9409906B2 (enExample) |
| EP (1) | EP2807165B1 (enExample) |
| JP (1) | JP6250556B2 (enExample) |
| KR (1) | KR102098122B1 (enExample) |
| CN (1) | CN104144931B (enExample) |
| AU (1) | AU2013212457B2 (enExample) |
| BR (1) | BR112014018524B1 (enExample) |
| CA (1) | CA2862140C (enExample) |
| CY (1) | CY1121799T1 (enExample) |
| DK (1) | DK2807165T3 (enExample) |
| ES (1) | ES2733946T3 (enExample) |
| HR (1) | HRP20191189T1 (enExample) |
| HU (1) | HUE044070T4 (enExample) |
| IL (1) | IL233587B (enExample) |
| LT (1) | LT2807165T (enExample) |
| NZ (1) | NZ627188A (enExample) |
| PL (1) | PL2807165T3 (enExample) |
| PT (1) | PT2807165T (enExample) |
| RS (1) | RS59002B1 (enExample) |
| SG (1) | SG11201404241SA (enExample) |
| SI (1) | SI2807165T1 (enExample) |
| SM (1) | SMT201900360T1 (enExample) |
| TR (1) | TR201909582T4 (enExample) |
| WO (1) | WO2013110198A1 (enExample) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102098122B1 (ko) | 2012-01-27 | 2020-04-07 | 유니버시떼 드 몬트리얼 | 피리미도[4,5-b]인돌 유도체 및 조혈 줄기 세포의 증식에서의 이의 용도 |
| JP6401773B2 (ja) * | 2013-03-11 | 2018-10-10 | ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン | Ｂｅｔブロモドメイン阻害剤およびこれを用いる治療方法 |
| US9757378B2 (en) | 2013-05-17 | 2017-09-12 | Universite De Montreal | Methods to modulate acute myeloid leukemia stem/progenitor cell expansion and/or differentiation |
| EP3110818B1 (en) * | 2014-02-28 | 2019-10-23 | The Regents of The University of Michigan | 9h-pyrimido[4,5-b]indoles and related analogs as bet bromodomain inhibitors |
| CN106414445B (zh) * | 2014-04-22 | 2020-07-03 | 蒙特利尔大学 | 化合物及其在扩增造血干细胞和/或造血祖细胞中的应用 |
| CN107208111B (zh) * | 2014-09-18 | 2021-07-06 | 蒙特利尔大学 | 用于增强病毒基因转移至人造血细胞的化合物和方法 |
| EA201791443A1 (ru) * | 2014-12-31 | 2018-01-31 | Антродженезис Корпорейшн | Естественные киллерные клетки и их применения |
| WO2016118780A1 (en) * | 2015-01-21 | 2016-07-28 | Fred Hutchinson Cancer Research Center | Point-of-care and/or portable platform for gene therapy |
| JP6954844B2 (ja) * | 2015-06-05 | 2021-10-27 | エマ−ケベック | 造血幹細胞を培養するため及び／又は造血幹細胞を前駆体へ分化させるための方法及びその使用 |
| EP3313420B1 (en) | 2015-06-25 | 2024-03-13 | The Children's Medical Center Corporation | Methods and compositions relating to hematopoietic stem cell expansion, enrichment, and maintenance |
| CN105316293A (zh) * | 2015-09-23 | 2016-02-10 | 广东颐养抗衰老研究院 | 一种体外获得造血干/祖细胞的方法 |
| JP2018535666A (ja) * | 2015-10-15 | 2018-12-06 | セルラリティ インコーポレイテッド | ナチュラルキラー細胞およびｉｌｃ３細胞ならびにそれらの使用 |
| US20190010495A1 (en) * | 2015-12-28 | 2019-01-10 | Novartis Ag | Compositions and methods for the treatment of hemoglobinopathies |
| AU2017235461B2 (en) | 2016-03-15 | 2023-02-23 | Children's Medical Center Corporation | Methods and compositions relating to hematopoietic stem cell expansion |
| JP2019519486A (ja) * | 2016-05-07 | 2019-07-11 | セルラリティ インコーポレイテッド | ナチュラルキラー細胞を使用して急性骨髄性白血病および多発性骨髄腫を処置する方法 |
| WO2018048346A1 (en) * | 2016-08-18 | 2018-03-15 | National University Of Singapore | Substituted azole derivatives for generation, proliferation and differentiation of hematopoietic stem and progenitor cells |
| EP3519577A1 (en) | 2016-09-28 | 2019-08-07 | Novartis AG | Porous membrane-based macromolecule delivery system |
| TW201839136A (zh) | 2017-02-06 | 2018-11-01 | 瑞士商諾華公司 | 治療血色素異常症之組合物及方法 |
| KR20250107976A (ko) | 2017-09-29 | 2025-07-14 | 인텔리아 테라퓨틱스, 인크. | 지질 나노파티클을 이용한 mRNA 전달의 체외 방법 |
| AU2018361971A1 (en) * | 2017-11-03 | 2020-06-04 | Universite De Montreal | Compounds and use thereof in the expansion of stem cells and/or progenitor cells |
| US20200338132A1 (en) * | 2018-01-03 | 2020-10-29 | Magenta Therapeutics Inc. | Compositions and methods for the expansion of hematopoietic stem and progenitor cells and treatment of inherited metabolic disorders |
| CA3091865A1 (en) | 2018-02-20 | 2019-08-29 | Universite De Montreal | Expansion of nk and dc cells in vivo mediating immune response |
| ES2979163T3 (es) * | 2018-10-31 | 2024-09-24 | Gilead Sciences Inc | Compuestos de 6-azabenzimidazol sustituidos como inhibidores de HPK1 |
| KR102329235B1 (ko) * | 2018-11-21 | 2021-11-22 | 한국화학연구원 | Irak4 저해제로서 신규의 삼중고리 화합물 |
| US11697799B2 (en) | 2019-04-15 | 2023-07-11 | Ossium Health, Inc. | System and method for extraction and cryopreservation of bone marrow |
| US20230073512A1 (en) * | 2019-12-18 | 2023-03-09 | Universite De Montreal | Modulators of cullin 3 adaptor kbtbd4 as anti-cancer compounds |
| WO2021123920A1 (en) | 2019-12-18 | 2021-06-24 | Novartis Ag | Compositions and methods for the treatment of hemoglobinopathies |
| AU2020411454A1 (en) | 2019-12-26 | 2022-07-14 | Nextgem Inc. | Method for culturing hematopoietic stem cells |
| EP4146797A1 (en) | 2020-05-06 | 2023-03-15 | Orchard Therapeutics (Europe) Limited | Treatment for neurodegenerative diseases |
| WO2021256977A1 (en) * | 2020-06-15 | 2021-12-23 | Subramaniam Agatheeswaran | Novel methods and compounds for protein degradation |
| EP4171593A4 (en) * | 2020-06-25 | 2024-07-03 | Angiocrine Bioscience, Inc. | Endothelial cells for mitigation of chemotherapy-induced toxicity |
| EP4181675A4 (en) | 2020-07-18 | 2024-04-24 | Ossium Health, Inc. | PERMEATION OF WHOLE VERTEBRATE BODIES WITH A CRYOPRETECTIVE AGENT USING VACUUM-ASSISTED DIFFUSION |
| AU2021360590A1 (en) | 2020-10-14 | 2023-06-15 | Ossium Health, Inc. | Systems and methods for extraction and cryopreservation of bone marrow |
| CN117279650A (zh) | 2020-12-18 | 2023-12-22 | 奥瑟姆健康公司 | 细胞治疗方法 |
| TW202309044A (zh) * | 2021-04-26 | 2023-03-01 | 日商住友製藥股份有限公司 | 氧呯衍生物 |
| WO2022232839A1 (en) | 2021-04-30 | 2022-11-03 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for improved production of primary cd34+ cells |
| US20250127809A1 (en) | 2021-06-23 | 2025-04-24 | Novartis Ag | Compositions and methods for the treatment of hemoglobinopathies |
| GB202111169D0 (en) | 2021-08-03 | 2021-09-15 | Adaptimmune Ltd | Methods of T cell production |
| CN114736862B (zh) * | 2022-05-18 | 2024-05-28 | 诺航生物技术研究院徐州有限公司 | 一种造血干细胞培养基和造血干细胞的体外扩增方法 |
| CN117164593A (zh) * | 2023-08-31 | 2023-12-05 | 贵州省天然产物研究中心 | 一种嘧啶并吲哚类化合物及其制备方法和应用、抗红白血病药物 |
| US11945818B1 (en) | 2023-09-06 | 2024-04-02 | King Faisal University | Pyrrolo[3,2-c]quinoline compounds as CK2 inhibitors |
| US11964981B1 (en) | 2023-09-18 | 2024-04-23 | King Faisal University | Substituted pyrimido[4,5-b]indoles as CK2 inhibitors |
| CN117229284B (zh) * | 2023-11-10 | 2024-02-06 | 上海泽德曼医药科技有限公司 | 三环稠杂环类化合物、其制备方法及其在医药上的应用 |
| US12012414B1 (en) | 2024-01-04 | 2024-06-18 | King Faisal University | Imidazo[1,5-a]pyrido[4,3-e]pyrimidines as CK2 inhibitors |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1262864A (en) * | 1968-03-29 | 1972-02-09 | Glaxo Lab Ltd | Diazacarbazoles |
| JPH08502721A (ja) | 1992-04-03 | 1996-03-26 | ジ・アップジョン・カンパニー | 医薬的に活性な二環式‐複素環アミン |
| IL112248A0 (en) | 1994-01-25 | 1995-03-30 | Warner Lambert Co | Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them |
| DE69619114T2 (de) * | 1995-07-06 | 2002-10-02 | Novartis Ag, Basel | Pyrolopyrimidine und verfahren zu ihrer herstellung |
| PT964865E (pt) | 1997-01-08 | 2003-06-30 | Upjohn Co | Aminas triciclicas farmaceuticamente activas |
| JP2002529502A (ja) | 1998-11-17 | 2002-09-10 | スミスクライン・ビーチャム・コーポレイション | 血小板減少症の治療法 |
| GC0000177A (en) | 1998-12-17 | 2006-03-29 | Smithkline Beecham | Thrombopoietin mimetics |
| AU4808300A (en) | 1999-04-30 | 2000-11-17 | Neurogen Corporation | 9h-pyrimido(4,5-b)indole derivatives: crf1 specific ligands |
| AU4692400A (en) | 1999-05-03 | 2000-11-17 | Smithkline Beecham Corporation | Cxcr-4 receptor antagonists - thrombopoietin mimetics |
| EP1213965B1 (en) | 1999-09-10 | 2006-01-18 | Smithkline Beecham Corporation | Thrombopoietin mimetics |
| ES2279769T3 (es) | 1999-09-24 | 2007-09-01 | Smithkline Beecham Corporation | Mimeticos de trombopoyetina. |
| WO2001034585A1 (en) | 1999-11-05 | 2001-05-17 | Smithkline Beecham Corporation | Semicarbazone derivatives and their use as thrombopoietin mimetics |
| JP2003515560A (ja) | 1999-12-06 | 2003-05-07 | スミスクライン・ビーチャム・コーポレイション | トロンボポイエチン模倣物 |
| CY2010012I2 (el) | 2000-05-25 | 2020-05-29 | Novartis Ag | Μιμητικα θρομβοποιητινης |
| CA2436288A1 (en) | 2000-12-19 | 2002-06-27 | Smithkline Beecham Corporation | Thrombopoietin mimetics |
| EP1370252A4 (en) | 2001-03-01 | 2006-04-05 | Smithkline Beecham Corp | Thrombopoietin mimetics |
| WO2002089746A2 (en) | 2001-05-09 | 2002-11-14 | The University Of Louisville Research Foundation, Inc. | Hematopoietic stem cell chimerism to treat autoimmune disease |
| EP1442039A1 (en) | 2001-10-31 | 2004-08-04 | Bayer HealthCare AG | Pyrimido (4,5-b) indole derivatives |
| AU2003248630A1 (en) | 2002-06-06 | 2003-12-22 | Smithkline Beecham Corporation | Thrombopoietin mimetics |
| EP1581527A4 (en) | 2002-12-13 | 2006-11-22 | Smithkline Beecham Corp | MIMETICS OF THROMBOPOIETINE |
| AU2003300522A1 (en) * | 2002-12-27 | 2004-07-22 | Bayer Healthcare Ag | 4-phenyl-pyrimido (4,5-b) indole derivatives |
| SG150387A1 (en) | 2003-05-02 | 2009-03-30 | Insception Bioscience Inc | Apparatus and methods for amplification of blood stem cell numbers |
| CA2542076C (en) | 2003-10-14 | 2013-02-26 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Substituted tricyclic compounds as protein kinase inhibitors |
| JP2008539277A (ja) * | 2005-04-28 | 2008-11-13 | スーパージェン， インコーポレイテッド | プロテインキナーゼインヒビター |
| BRPI0613460A2 (pt) | 2005-07-14 | 2011-01-11 | Irm Llc | compostos e composições como inibidores de proteìna cinase |
| EP1749822B1 (en) * | 2005-08-05 | 2008-10-15 | Hybrigenics S.A. | Novel cysteine protease inhibitors and their therapeutic applications |
| BRPI0616994A2 (pt) | 2005-08-15 | 2011-07-05 | Irm Llc | compostos e composições como miméticos de tpo |
| WO2007145227A1 (ja) | 2006-06-14 | 2007-12-21 | Chugai Seiyaku Kabushiki Kaisha | 造血幹細胞増加促進剤 |
| JP2008050355A (ja) * | 2006-08-21 | 2008-03-06 | Eisai R & D Management Co Ltd | 造血幹細胞を増殖、分化および／または循環系内に動員させる医薬組成物および方法 |
| WO2008028645A1 (en) | 2006-09-05 | 2008-03-13 | Aplagen Gmbh | Peptides binding the tpo receptor |
| US20080207632A1 (en) * | 2006-10-31 | 2008-08-28 | Supergen, Inc. | Protein kinase inhibitors |
| EP2094839B1 (en) | 2006-12-08 | 2020-02-05 | University of Rochester | Expansion of hematopoietic stem cells |
| EP2121692B1 (en) * | 2006-12-22 | 2013-04-10 | Incyte Corporation | Substituted heterocycles as janus kinase inhibitors |
| JP2010525836A (ja) * | 2007-05-04 | 2010-07-29 | ホワイトヘッド・インスティテュート・フォー・バイオメディカル・リサーチ | ヒト造血幹細胞のｅｘｖｉｖｏ増殖 |
| EP2170886A1 (en) | 2007-07-02 | 2010-04-07 | Cancer Research Technology Limited | 9h-pyrimido[4,5-b]indoles, 9h-pyrido[4',3':4,5]pyrrolo[2,3-d]pyridines, and 9h-1,3,6,9-tetraaza-fluorenes as chk1 kinase function inhibitors |
| US7982035B2 (en) * | 2007-08-27 | 2011-07-19 | Duquesne University Of The Holy Spirit | Tricyclic compounds having antimitotic and/or antitumor activity and methods of use thereof |
| PE20100362A1 (es) | 2008-10-30 | 2010-05-27 | Irm Llc | Derivados de purina que expanden las celulas madre hematopoyeticas |
| JP2010193879A (ja) * | 2009-01-27 | 2010-09-09 | Jms Co Ltd | 臍帯血造血幹細胞の増殖制御方法およびその用途 |
| WO2011056739A1 (en) | 2009-11-03 | 2011-05-12 | Glaxosmithkline Llc | Compounds and methods |
| EP2686320B1 (en) * | 2011-03-15 | 2016-05-18 | Merck Sharp & Dohme Corp. | Tricyclic gyrase inhibitors |
| KR102098122B1 (ko) | 2012-01-27 | 2020-04-07 | 유니버시떼 드 몬트리얼 | 피리미도[4,5-b]인돌 유도체 및 조혈 줄기 세포의 증식에서의 이의 용도 |
-
2013
- 2013-01-25 KR KR1020147023818A patent/KR102098122B1/ko active Active
- 2013-01-25 DK DK13740815.9T patent/DK2807165T3/da active
- 2013-01-25 NZ NZ627188A patent/NZ627188A/en unknown
- 2013-01-25 TR TR2019/09582T patent/TR201909582T4/tr unknown
- 2013-01-25 CA CA2862140A patent/CA2862140C/en active Active
- 2013-01-25 ES ES13740815T patent/ES2733946T3/es active Active
- 2013-01-25 WO PCT/CA2013/050052 patent/WO2013110198A1/en not_active Ceased
- 2013-01-25 EP EP13740815.9A patent/EP2807165B1/en active Active
- 2013-01-25 LT LTEP13740815.9T patent/LT2807165T/lt unknown
- 2013-01-25 BR BR112014018524-7A patent/BR112014018524B1/pt active IP Right Grant
- 2013-01-25 HR HRP20191189TT patent/HRP20191189T1/hr unknown
- 2013-01-25 PL PL13740815T patent/PL2807165T3/pl unknown
- 2013-01-25 PT PT13740815T patent/PT2807165T/pt unknown
- 2013-01-25 SI SI201331486T patent/SI2807165T1/sl unknown
- 2013-01-25 SG SG11201404241SA patent/SG11201404241SA/en unknown
- 2013-01-25 US US14/374,953 patent/US9409906B2/en active Active
- 2013-01-25 HU HUE13740815A patent/HUE044070T4/hu unknown
- 2013-01-25 RS RS20190858A patent/RS59002B1/sr unknown
- 2013-01-25 JP JP2014553589A patent/JP6250556B2/ja active Active
- 2013-01-25 AU AU2013212457A patent/AU2013212457B2/en active Active
- 2013-01-25 CN CN201380007006.5A patent/CN104144931B/zh active Active
- 2013-01-25 SM SM20190360T patent/SMT201900360T1/it unknown
-
2014
- 2014-07-10 IL IL23358714A patent/IL233587B/en active IP Right Grant
-
2016
- 2016-02-18 US US15/047,292 patent/US20160222017A1/en not_active Abandoned
- 2016-12-02 US US15/368,082 patent/US10336747B2/en active Active
-
2019
- 2019-07-05 CY CY20191100713T patent/CY1121799T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015504902A5 (enExample) | ||
| JP2017513897A5 (enExample) | ||
| HRP20191189T1 (hr) | Pirimido[4,5-b]indol derivati i njihova primjena u ekspanziji hematopoetskih matičnih stanica | |
| JP2023171766A5 (enExample) | ||
| AU2018253115B2 (en) | Aryl hydrocarbon receptor antagonists and uses thereof | |
| RU2422513C2 (ru) | Способы экспансии популяций миелоидных клеток и их использование | |
| EP3134409B1 (en) | Compounds and use thereof in the expansion of hematopoietic stem cells and/or hematopoietic progenitor cells | |
| JP2008517948A5 (enExample) | ||
| JP2013523614A5 (enExample) | ||
| Bacigalupo et al. | Haploidentical donor transplants for severe aplastic anemia | |
| JP2017524025A5 (enExample) | ||
| FI3406251T3 (fi) | Pyruvaattikinaasin aktivaattoreita terapeuttista käyttöä varten | |
| Bastani et al. | The quest for the holy grail: overcoming challenges in expanding human hematopoietic stem cells for clinical use | |
| Aljagthmi et al. | Hematopoietic stem cells: Understanding the mechanisms to unleash the therapeutic potential of hematopoietic stem cell transplantation | |
| JP7502813B2 (ja) | 汎用型の臨床における異体ｄｎｔ細胞の複数回再注入用の効率的体外増幅方法 | |
| JP7467358B2 (ja) | 免疫応答を媒介するｉｎ ｖｉｖｏでのＮＫ細胞およびＤＣ細胞の拡大 | |
| JP2018516089A (ja) | 造血幹細胞を培養するため及び／又は造血幹細胞を前駆体へ分化させるための方法及びその使用 | |
| US12060310B2 (en) | Compositions and methods of using itaconic acid derivatives | |
| Radtke et al. | Human multipotent hematopoietic progenitor cell expansion is neither supported in endothelial and endothelial/mesenchymal co-cultures nor in NSG mice | |
| JP2017520275A5 (enExample) | ||
| WO2020084310A1 (en) | Stem cell therapy | |
| Zarrabi et al. | Pf 00835231 is a prodrug with the phosphate group being cleaved in vivo to yield the active agent PF-00835231. Menu | |
| Zhang et al. | 704. Ex vivo and in vivo expansion of HoxB4-Transduced CD34+ cells from dogs, baboons, macaques and humans | |
| WO2011143521A2 (en) | Enhanced homing and engraftment of hematopoietic stem cells using cd26 inhibitors |